Quarterly ResultMay 5, 2026, 04:15 PM
Jazz Pharma Q1 Net Income $293.1M; Revenue $1.07B, up 19.1%
AI Summary
Jazz Pharmaceuticals plc reported a strong first quarter for 2026, with total revenues increasing by 19.1% to $1,068.9 million. The company achieved a net income of $293.1 million, a substantial turnaround from a net loss in the prior year period, driven in part by a $122.8 million gain from the sale of a Priority Review Voucher. Basic EPS improved significantly to $4.73.
Key Highlights
- Total revenues for Q1 2026 increased 19.1% to $1,068.9 million from $897.8 million in Q1 2025.
- Net income for Q1 2026 was $293.1 million, a significant improvement from a net loss of $92.5 million in Q1 2025.
- Basic earnings per ordinary share were $4.73 in Q1 2026, compared to a loss of $1.52 in Q1 2025.
- Diluted earnings per ordinary share were $4.43 in Q1 2026, compared to a loss of $1.52 in Q1 2025.
- The company recognized a pre-tax gain of $122.8 million from the sale of a rare pediatric disease Priority Review Voucher (PRV) in January 2026.
- Cash and cash equivalents stood at $1,844.3 million as of March 31, 2026, up from $1,391.9 million at December 31, 2025.
- Net cash provided by operating activities was $408.2 million for Q1 2026.
Price Impact
More from JAZZ